Cisapride: limited access and alternatives.
The withdrawal of cisapride from the market will present challenges for physicians treating patients with nocturnal heartburn, gastroparesis, and dyspepsia. However, alternatives to the drug exist, and it will continue to be available under a limited-access program for patients for whom other drug treatments fail.
Richter
J E
JE
Department of Gastroenterology, Cleveland Clinic, USA. richtej@ccf.org
D000897:Anti-Ulcer Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000139:chemically induced* / Q000401:mortality; D020117:Cisapride / Q000009:adverse effects* / Q000627:therapeutic use; D004335:Drug and Narcotic Control / Q000458:organization & administration*; D004415:Dyspepsia / Q000188:drug therapy; D005260:Female; D005764:Gastroesophageal Reflux / Q000188:drug therapy; D006356:Heartburn / Q000188:drug therapy; D006801:Humans; D008297:Male; D018570:Risk Assessment; D014481:United States
D000897:Anti-Ulcer Agents; D020117:Cisapride